BSECompany Update3d ago · 16 Aug 2026, 09:01 am

Newspaper Publication for the Un-Audited Financial Results for the quarter ended June 30, 2026 and declaration of Interim Dividend for the FY ending 2026-27.

Natco Pharma Ltd · 524816

✦ AI Summary▲ PositiveResults

Natco Pharma Ltd has published un-audited financial results for Q1 FY 2026-27 and declared an interim dividend. The results and dividend declaration were published in newspapers on August 15, 2026, and are available on the company's website.

Analysis Scores

Earnings Impact8/10

Growth Catalyst5/10

Governance Concern2/10

Regulatory Risk1/10

Balance Sheet Risk3/10

Liquidity Impact9/10

Market Sentiment8/10

✦ Ask a Question

Ask anything about this announcement — AI will answer based on the filing content.

Full Announcement

Natco Pharma Ltd - 524816 - Announcement under Regulation 30 (LODR)-Newspaper Publication

Attachments (1)

📄

30da9e27-ae13-4bc6-ba39-c50064955b1c.pdf

pdf

Download →

View document text

August 16, 2026 Corporate Relationship Department Manager – Listing M/s. BSE Ltd. M/s. National Stock Exchange of India Ltd Mumbai 400 001 Mumbai 400 051 Scrip Code: 524816 Scrip Code: NATCOPHARM Dear Sir / Madam Sub: - Paper Publications Pursuant to Regulation 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended from time to time, please find enclosed the copies of the newspaper Publications as appeared on August 15, 2026 in Business Line, Financial Express and Nava Telangana regarding the Un-audited Financial Results of the Company for the quarter ended June 30, 2026 and declaration of Interim Dividend for FY ending 2026-27. The above publications are available on the website of the Company at www.natcopharma.co.in Thanking you Yours faithfully For NATCO Pharma Limited Ch. Venkat Ramesh Company Secretary & Compliance Officer Encl: as above